albumin-bound paclitaxel

Phase 3Small molecule

albumin-bound paclitaxel is one of 526 small molecule programs targeting Advanced/Metastatic Solid Tumors. It is currently in Phase 3.

Indications

Total Trials

Active Trials

525

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced/metastatic Solid TumorsNot yet recruiting

Pancreatic CystsActive, not recruiting

Esophageal Squamous Cell Carcinoma (ESCC)Not yet recruiting

TreatmentNot yet recruiting

CholangiocarcinomaActive, not recruiting

GC/GEJCRecruiting

Triple-Negative Breast CancerRecruiting

Oropharyngeal CancerActive, not recruiting

ImmunotherapyRecruiting

Neoadjuvant TherapyRecruiting

Advanced/metastatic Solid TumorsPhase 2

Not yet recruiting

Pancreatic CystsPreclinical

Active, not recruiting

Esophageal Squamous Cell Carcinoma (ESCC)Phase 2

Not yet recruiting

TreatmentPhase 2

Not yet recruiting

CholangiocarcinomaPreclinical

Active, not recruiting

GC/GEJCPhase 2

Recruiting

Triple-Negative Breast CancerPhase 2

Recruiting

Oropharyngeal CancerPhase 2

Active, not recruiting

ImmunotherapyPhase 2

Recruiting

Neoadjuvant TherapyPhase 3

Recruiting

Showing 10 of 26 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

albumin-bound paclitaxel

Bristol-Myers Squibb

Phase 3

12 2

Lexiscan

Astellas

Preclinical

1 3

Voltaren

Novartis

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Duragesic-100

CCephalon

Preclinical

2 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 8

Duragesic

CCephalon

Preclinical

1 9

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 10

Tricor

JJagotec

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Second-Line Treatment

NCT06028633

Phase 2Not yet recruiting

Neoadjuvant Chemoimmunotherapy

NCT07346807

Phase 1/2Active, not recruiting

Advanced or Metastatic Solid Tumors

NCT04396821

Post-ApprovalRecruiting

Pancreatic Cancer

NCT05035147

Phase 1/2Recruiting

Esophageal Cancer

NCT04278287

Phase 2Not yet recruiting

Esophageal Squamous Carcinoma

NCT07019181

Clinical

Trials by Indication[1]

Breast Cancer12 trials

Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients

Active, not recruiting·FFudan University·Phase 2·NCT04418154·70 enrolled

Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193206·123 enrolled

Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00093145·32 enrolled

Show 9 more trials

Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study

Not yet recruiting·CChinese Academy of Medical Sciences·N/A·NCT05287308·500 enrolled

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer

Not yet recruiting·FFudan University·Phase 2·NCT06404463·76 enrolled

HR Positive, HER2 Negative Advanced Breast Cancer With Progression After Endocrine Therapy

Unknown status·TTaizhou EOC Pharma Co., Ltd.·Phase 2·NCT05322720·50 enrolled

Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer

Unknown status·PPeking Union Medical College·Phase 1/2·NCT03994107·40 enrolled

Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

Recruiting·FFujian Cancer Hospital·Phase 1/2·NCT05019690·29 enrolled

Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 4·NCT05291910·70 enrolled

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer

Not yet recruiting·FFudan University·Phase 2·NCT06404736·73 enrolled

A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer

Recruiting·NNanjing Leads Biolabs Co.,Ltd·Phase 1/2·NCT07281976·220 enrolled

A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)

Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 3·NCT07648914·446 enrolled

Pancreatic Cancer6 trials

Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer

Not yet recruiting·JJinling Hospital, China·Phase 2·NCT06177522·30 enrolled

Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00398086·67 enrolled

Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 4·NCT05035147·934 enrolled

Show 3 more trials

IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer

Recruiting·IInxMed (Shanghai) Co., Ltd.·Phase 1/2·NCT05827796·70 enrolled

A Trial of NS/GEMOX Chemotherapy in Patients With Untreated Pancreatic Cancer ( HZ-NS/GEMOX-PC )

Unknown status·YYanqiao Zhang·Phase 2·NCT03825328·30 enrolled

A Multi-cohort Exploratory Study to Evaluate the Efficacy and Safety of Albumin-bound Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic Cancer

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07828756·147 enrolled

Gastric Cancer5 trials

Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT05669807·184 enrolled

Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer

Completed·SSun Yat-sen University·Phase 2·NCT02229058·73 enrolled

Phase II Study of Albumin Bound Paclitaxel With 5-FU and CF as Second Line in Taxanes Naive Advanced Gastric Cancer

Unknown status·SSun Yat-sen University·Phase 2·NCT02229045·37 enrolled

Show 2 more trials

Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer

Terminated·HHuazhong University of Science and Technology·Phase 2·NCT04294784·58 enrolled

Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis

Enrolling by invitation·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT06487715·42 enrolled

Esophageal Squamous Cell Carcinoma4 trials

PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Unknown status·FFujian Cancer Hospital·Phase 2·NCT05007145·92 enrolled

A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.

Unknown status·LLee's Pharmaceutical Limited·Phase 1/2·NCT04460066·70 enrolled

Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT07046221·60 enrolled

Show 1 more trial

Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma

Unknown status·TTao Jiang·Phase 2·NCT05552651·40 enrolled

Esophageal Cancer3 trials

Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer

Completed·—·Phase 2·NCT04821765·35 enrolled

Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer

Not yet recruiting·SShanghai Zhongshan Hospital·Phase 2·NCT06599775·42 enrolled

Chemoradiotherapy in Unresectable Esophageal Cancer

Recruiting·—·Phase 1/2·NCT04278287·105 enrolled

35 more indications

Advanced Solid Tumors2 trials

HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors

Recruiting·—·Phase 1/2·NCT05681650·30 enrolled

TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors

Not yet recruiting·FFujian Cancer Hospital·Phase 1·NCT05648994·30 enrolled

Adenocarcinoma2 trials

Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma

Recruiting·FFudan University··NCT07389876·250 enrolled

Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00844649·861 enrolled

Advanced/Metastatic Solid Tumors2 trials

CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors

Not yet recruiting·—·Phase 1/2·NCT06939270·30 enrolled

Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors

Recruiting·—·Phase 1/2·NCT05693844·15 enrolled

Patients With Advanced Solid Tumors2 trials

Study of SRF617 in Patients With Advanced Solid Tumors

Completed·CCoherus Oncology, Inc.·Phase 1·NCT04336098·85 enrolled

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

Active, not recruiting·FFBD Biologics Limited·Phase 1/2·NCT06771622·500 enrolled

Nasopharyngeal Carcinoma2 trials

Toripalimab Combined With Chemoradiotherapy in Patients With Locoregionally-advanced Nasopharyngeal Carcinoma

Unknown status·FFirst People's Hospital of Foshan·Phase 2·NCT04446663·50 enrolled

Paclitaxel (Albumin-bound) Combined With Radiotherapy for the Treatment of Early Stage Nasopharyngeal Carcinoma

Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 3·NCT04766359·364 enrolled

Non-Small Cell Lung Cancer2 trials

AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer

Recruiting·HHenan Cancer Hospital·Phase 2·NCT05377658·43 enrolled

Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00540514·1,052 enrolled

Cervical Cancer2 trials

Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial

Unknown status·LLei Li·Phase 2·NCT05290935·122 enrolled

Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial

Recruiting·SSun Yat-sen University·Phase 3·NCT05367206·280 enrolled

Second-line Treatment2 trials

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Not yet recruiting·PPeking University First Hospital·Phase 2·NCT06028633·28 enrolled

Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Cancer

Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT06791148·45 enrolled

Esophageal Squamous Carcinoma1 trial

Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma

Not yet recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 2·NCT07019181·26 enrolled

Soft Tissue Sarcoma1 trial

Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma.

Unknown status·HHenan Cancer Hospital·Phase 2·NCT05189483·40 enrolled

Unknown status·HHenan Cancer Hospital·Phase 2·NCT03942068·35 enrolled

Head and Neck1 trial

Albumin-bound Paclitaxel Combined With Cisplatin Versus Docetaxel Combined With Cisplatin Induced Chemotherapy in Advanced Head and Neck Squamous Tummor

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 4·NCT04766827·116 enrolled

Oropharyngeal Cancer1 trial

Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)

Active, not recruiting·—·Phase 2·NCT06009861·110 enrolled

Immunotherapy1 trial

Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC

Recruiting·—·Phase 2·NCT06725498·50 enrolled

Nab-paclitaxel1 trial

Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma

Unknown status·—·N/A·NCT04443036·44 enrolled

Pancreatic cysts1 trial

Endoscopic Abraxane Injection Into Pancreatic Cysts

Terminated·MMassachusetts General Hospital·N/A·NCT01698710·5 enrolled

Neoadjuvant Chemotherapy1 trial

Effect of Albumin-bound Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian, Fallopian Tube or Peritoneal Cancer: A Phase 2 Single Center Clinical Trial

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05316376·78 enrolled

Neoadjuvant Chemoimmunotherapy1 trial

Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer

Not yet recruiting·SShanghai Zhongshan Hospital·Phase 2·NCT07346807·69 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Completed·HHonorHealth Research Institute·Phase 2·NCT02754726·35 enrolled

Resectable NSCLC1 trial

Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE）

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT04459611·60 enrolled

Neoadjuvant Treatment1 trial

Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC

Recruiting·TTang-Du Hospital·Phase 2·NCT06055738·20 enrolled

Treatment1 trial

Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

Not yet recruiting·PPeking University Shenzhen Hospital·Phase 2·NCT06692491·200 enrolled

Penile Cancer1 trial

TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer

Completed·SSun Yat-sen University·Phase 2·NCT04475016·29 enrolled

Urothelial Carcinoma1 trial

A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma

Unknown status·LLee's Pharmaceutical Limited·Phase 1·NCT04603846·20 enrolled

Lung Cancer1 trial

Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT02525653·40 enrolled

Paclitaxel1 trial

Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA

Not yet recruiting·PPeking University·Phase 2·NCT06222944·90 enrolled

Advanced or Metastatic Solid Tumors1 trial

A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

Active, not recruiting·SSuzhou Transcenta Therapeutics Co., Ltd.·Phase 1/2·NCT04396821·150 enrolled

Triple-Negative Breast Cancer1 trial

A Prospective, Randomized, Open Label Clinical Study Evaluating Efficacy and Safety of Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic Triple Negative Breast Cancer

Recruiting·TThe First Affiliated Hospital of Bengbu Medical University·Phase 2·NCT05192798·128 enrolled

GC/GEJC1 trial

A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric Cancer

Recruiting·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT07770113·50 enrolled

Melanoma, Cutaneous Malignant1 trial

A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator's Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301)

Recruiting·IImmatics US, Inc.·Phase 3·NCT06743126·360 enrolled

Solid Tumor1 trial

A Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JS015 Combination Therapy in Patients With Advanced Solid Tumors

Completed·SShanghai Junshi Bioscience Co., Ltd.·Preclinical·NCT06139211·66 enrolled

Esophageal Squamous Cell Carcinoma (ESCC)1 trial

Neoadjuvant Short-Course Radiotherapy Followed by Tislelizumab Combined With Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma: A Prospective, Multicenter, Exploratory Study

Not yet recruiting·TTang-Du Hospital·Phase 2·NCT07678580·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 73 trial records for albumin-bound paclitaxel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — albumin-bound paclitaxel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for albumin-bound paclitaxel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bristol-Myers Squibb

albumin-bound paclitaxel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Breast Cancer12 trials

Pancreatic Cancer6 trials

Gastric Cancer5 trials

Esophageal Squamous Cell Carcinoma4 trials

Esophageal Cancer3 trials

Advanced Solid Tumors2 trials

Adenocarcinoma2 trials

Advanced/Metastatic Solid Tumors2 trials

Patients With Advanced Solid Tumors2 trials

Nasopharyngeal Carcinoma2 trials

Non-Small Cell Lung Cancer2 trials

Cervical Cancer2 trials

Second-line Treatment2 trials

Esophageal Squamous Carcinoma1 trial

Soft Tissue Sarcoma1 trial

Neoadjuvant Therapy1 trial

Head and Neck Squamous Cell Carcinoma1 trial

Cholangiocarcinoma1 trial

Ovarian Cancer1 trial

Head and Neck1 trial

Oropharyngeal Cancer1 trial

Immunotherapy1 trial

Nab-paclitaxel1 trial

Pancreatic cysts1 trial

Neoadjuvant Chemotherapy1 trial

Neoadjuvant Chemoimmunotherapy1 trial

Pancreatic Ductal Adenocarcinoma1 trial

Resectable NSCLC1 trial

Neoadjuvant Treatment1 trial

Treatment1 trial

Penile Cancer1 trial

Urothelial Carcinoma1 trial

Lung Cancer1 trial

Paclitaxel1 trial

Advanced or Metastatic Solid Tumors1 trial

Triple-Negative Breast Cancer1 trial

GC/GEJC1 trial

Melanoma, Cutaneous Malignant1 trial

Solid Tumor1 trial

Esophageal Squamous Cell Carcinoma (ESCC)1 trial

References

Drug Info

Quick Facts

Related News